Aprea Therapeutics (NASDAQ:APRE) Shares Down 2.5% – Here’s What Happened

Aprea Therapeutics, Inc. (NASDAQ:APRE) dropped 2.5% during trading on Monday . The stock traded as low as $2.34 and last traded at $2.34. Approximately 10,321 shares were traded during mid-day trading, a decline of 45% from the average daily volume of 18,909 shares. The stock had previously closed at $2.40.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Aprea Therapeutics in a research report on Wednesday, January 15th.

Aprea Therapeutics Price Performance

The firm has a 50-day simple moving average of $3.26 and a 200 day simple moving average of $3.29. The company has a market capitalization of $12.83 million, a PE ratio of -0.84 and a beta of 0.82.

Institutional Investors Weigh In On Aprea Therapeutics

Hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets purchased a new stake in shares of Aprea Therapeutics during the fourth quarter valued at approximately $43,000. Stonepine Capital Management LLC increased its stake in Aprea Therapeutics by 8.8% during the 4th quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock worth $491,000 after buying an additional 12,047 shares during the period. LPL Financial LLC purchased a new stake in Aprea Therapeutics during the 4th quarter worth $53,000. Finally, Landscape Capital Management L.L.C. acquired a new position in Aprea Therapeutics in the 4th quarter worth $116,000. 34.19% of the stock is currently owned by hedge funds and other institutional investors.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.